Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by YHB Investment Advisors Inc.

YHB Investment Advisors Inc. cut its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 21,996 shares of the medical equipment provider’s stock after selling 763 shares during the quarter. Intuitive Surgical comprises approximately 0.9% of YHB Investment Advisors Inc.’s portfolio, making the stock its 26th largest holding. YHB Investment Advisors Inc.’s holdings in Intuitive Surgical were worth $10,806,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of ISRG. Mirador Capital Partners LP grew its position in Intuitive Surgical by 1.4% during the third quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider’s stock worth $1,732,000 after buying an additional 50 shares during the period. Advisors Asset Management Inc. grew its position in shares of Intuitive Surgical by 18.1% in the first quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock valued at $2,945,000 after purchasing an additional 1,129 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its position in shares of Intuitive Surgical by 617.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 89,069 shares of the medical equipment provider’s stock valued at $39,622,000 after purchasing an additional 76,649 shares during the last quarter. Brookstone Capital Management grew its position in shares of Intuitive Surgical by 22.4% in the second quarter. Brookstone Capital Management now owns 12,530 shares of the medical equipment provider’s stock valued at $5,340,000 after purchasing an additional 2,289 shares during the last quarter. Finally, M&G Plc grew its position in shares of Intuitive Surgical by 53.5% in the second quarter. M&G Plc now owns 5,069 shares of the medical equipment provider’s stock valued at $2,256,000 after purchasing an additional 1,766 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Brian Edward Miller sold 2,553 shares of the business’s stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $515.00, for a total value of $1,314,795.00. Following the sale, the executive vice president now directly owns 7,066 shares in the company, valued at $3,638,990. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, insider Mark Brosius sold 2,115 shares of Intuitive Surgical stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $491.91, for a total value of $1,040,389.65. Following the transaction, the insider now directly owns 295 shares of the company’s stock, valued at $145,113.45. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Brian Edward Miller sold 2,553 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $515.00, for a total transaction of $1,314,795.00. Following the completion of the transaction, the executive vice president now directly owns 7,066 shares in the company, valued at approximately $3,638,990. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 51,455 shares of company stock worth $24,911,155 in the last ninety days. 0.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ISRG. Truist Financial increased their price target on shares of Intuitive Surgical from $520.00 to $570.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Mizuho raised their target price on shares of Intuitive Surgical from $440.00 to $500.00 in a research note on Thursday, October 17th. Piper Sandler reissued an “overweight” rating and issued a $538.00 target price (up previously from $495.00) on shares of Intuitive Surgical in a research note on Friday, October 18th. Raymond James raised their price target on shares of Intuitive Surgical from $500.00 to $540.00 and gave the company an “outperform” rating in a report on Monday, October 14th. Finally, Morgan Stanley raised their price target on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $513.74.

Intuitive Surgical Trading Down 1.0 %

ISRG stock opened at $512.58 on Thursday. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $523.34. The company has a market capitalization of $181.81 billion, a price-to-earnings ratio of 92.52, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39. The firm’s 50-day moving average is $486.71 and its two-hundred day moving average is $440.96.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.